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UnderservedBackground: The US Preventative Service Task Force recommends that physicians perform a genetic risk assess-
ment to identify women at risk for BRCA1/2 mutations associated with hereditary breast and ovarian cancer
(HBOC) syndrome. However, outcomes data after a diagnosis of HBOC syndrome especially in diverse popula-
tions, are minimal. Here we asked if genetic screening of high-risk underserved women identiﬁed in the mam-
mogram population reduces cancer incidence.
Methods:We evaluated 61,924 underserved women at screening mammography for family histories suggestive
of HBOC syndrome over the course of 21months. Data were collected retrospectively from patients at two safety
net hospitals through chart review. A computermodelwas used to calculate the long-termeffect of this screening
on cancer incidence by assessing both the mutation detection rate and the completion of prophylactic surgeries
in BRCA1/2mutation carriers.
Findings:We identiﬁed 20 of the 85 (23.5%) expected BRCA1/2mutation carriers in the underserved population.
The frequencies of prophylactic mastectomies and oophorectomies in the mutation carriers were 25% and 40%,
respectively. Using these data, our model predicted only an 8.8% reduction in both breast and ovarian cancer in
the underserved patients. This contrasts with a 57% reduction in breast cancer and 51% reduction in ovarian can-
cer in an insured reference population. Our data indicate that underserved patients with HBOC syndrome are dif-
ﬁcult to identify and when identiﬁed are limited in their ability to adhere to NCCN guidelines for cancer
prevention.
Interpretation: Screening for women at risk for HBOC syndrome in mammogram populations will only prevent
cancers if we can increase compliance with management guidelines. This study provides prototypic baseline
data for step-wise analysis of the efﬁcacy of the use of family history analysis in the mammography setting for
detection and management of HBOC syndrome.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
It is unknown what impact screening underserved populations for
genetic risks for cancer has both on patients' compliance with manage-
ment guidelines and on the ultimate goal of reducing cancer incidence.
The hereditary breast and ovarian cancer (HBOC) syndrome is among
the most common inherited cancer predisposition syndromes (Ford
et al., 1998; Lindor et al., 2008), making groups of patients with
BRCA1/2mutations suitable populations to use to examine the beneﬁtsCenter, 5323 Harry Hines Blvd.,
oss).
. This is an open access article underof screening. For patients carrying these mutations, approximately 57%
of women with a BRCA1 mutation and 49% of women with a BRCA2
mutation will develop breast cancer by the age of 70 (Chen et al.,
2006). The average risk for ovarian cancer in patients with a BRCA1
mutation is 40% and in patients with a BRCA2 mutation, 18% (Chen
et al., 2006). While these are rare syndromes that cause an estimated
5–10% of all breast and 23% of ovarian cancers, individuals carrying
these mutations have the highest cancer incidence of any known
group. It has been estimated that 348,274 women in the United
States over the age of 20 have a BRCA gene mutation (Drohan et al.,
2012). After 14 years of BRCA gene testing, we have only identiﬁed
approximately 50,000 of these female mutation carriers (Drohan
et al., 2012). Seventy percent of BRCA mutation carriers with breastthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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main unidentiﬁed (Drohan et al., 2012; Bellcross et al., 2009).
Population based screening programs to identify more HBOC pa-
tients in the primary care setting have been proposed by many. The
US Center for Disease Control's (CDC's) ofﬁce of Public Health Genomics
has classiﬁed screening for a family history of cancer to identify patients
with HBOC syndrome as a tier one application (i.e. evidence supports
their implementation into medical practice and surveillance) (Khoury
et al., 2010; Dotson et al., 2014). However, population screening out-
comes data, especially in underserved communities, are scant. In 2013,
the US Preventative Services Task Force (USPSTF) recommended genet-
ic risk assessment and, if warranted, BRCAmutation testing in asymp-
tomatic women with a family history of breast and ovarian cancer
(Nelson et al., 2014). The goal of this recommendation is to both mini-
mize unproductive genetic referrals and identify more BRCA1/2muta-
tion carriers. A number of brief family history of cancer screening tools
have been successfully used to identify HBOC patients in small popula-
tions and are recommended by the USPSTF (Bellcross et al., 2009;
Dominguez et al., 2005; Evans et al., 2004; Gilpin et al., 2000; Hoskins
et al., 2006). However, there are no studies that quantitate the reduction
of cancer cases as a result of large-scale population screening to identify
patients with HBOC syndrome.
The goal of population screening for at-risk patients should be not
only to identify mutation carriers, but also to improve their compli-
ance with management recommendations to prevent cancers. How-
ever, since compliance rates are unknown, so too are the beneﬁts of
screening, especially in underserved communities. Here we mea-
sured patient compliance to NCCN management guidelines and
rates of prophylactic surgery in an underserved HBOC syndrome
patient cohort that was identiﬁed based on their family history of
cancer at the time of a screening mammogram. We calculated the
change in population cancer incidence over time based on the
number of BRCA1/2 mutation carriers we identiﬁed and the rate of
prophylactic surgeries done to identify opportunities to improve
cancer prevention.
2. Patients and Methods
2.1. Participants
From October 1st, 2011 to June 30th, 2013 (21 months), we
screened for a family history of cancer in 96,055 mammogram pa-
tients for possible HBOC syndrome (Bellcross et al., 2009; Bellcross,
2010). The underserved study population was from two county hos-
pitals (n = 61,924; Parkland Memorial and John Peter Smith (JPS)
hospitals in Dallas and Fort Worth, Texas, respectively) and for refer-
ence a primarily insured population from our private hospital (n =
34,131; UT Southwestern Medical Center in Dallas). Parkland and
JPS hospitals are the only safety net facilities in their counties serving
patients with incomes below 200% of the federal poverty level. Many
of the physicians at Parkland Memorial also work at UT Southwest-
ern Medical Center. However, the staff at the JPS hospital is com-
posed of private community board certiﬁed physicians. The genetic
counselors at all sites are from the UT Southwestern cancer genetics
program. Both safety net facilities have had a cancer genetics pro-
gram in place since 2008 and their physicians are experienced in
the management of hereditary cancer syndromes (Pirzadeh, 2009).
All facilities offer HBOC patients prophylactic surgeries.
The 96,055 patients represented all women attending mammogra-
phy during this time. Of those, 4% (n = 3928 patients) did not provide
family history information. Because of this they were considered non-
informative and were not studied further. Our study populations
spanned 6 counties covering an area of 4688 mi2, including both rural
and urban patients. The CancerGene Connect software was used to
track all the patients identiﬁed as high-risk and their compliance at
each step of the screening process (Pritzlaff et al., 2014). All participantsprovided informed consent. This studywas approved by the Institution-
al Review Board at UT Southwestern Medical Center.
2.2. HBOC Screening
To implement family history of cancer screening for possible HBOC
syndrome in both the insured and underserved communities, we used
the referral screening tool (RST) developed by the CDC (Bellcross
et al., 2009; Bellcross, 2010). This tool identiﬁed high-risk patients
based on a family history of cancerwhowere appropriate for HBOC test-
ing in both populations. We modiﬁed the RST to include breast cancer
patients diagnosed before the age of 45 and all ovarian cancer patients.
This was to ensure that we could identify high-risk patients based on
the NCCN genetic testing guidelines, including those who may not
have previously been offered genetic services. As expected, approxi-
mately 5% of mammogram patients warranted a genetics referral (Fig.
1) (Bellcross et al., 2009; Dominguez et al., 2005; Brannon Traxler
et al., 2014). A genetic patient navigator called all underserved patients
identiﬁed as high-risk and offered them follow-up services. Thiswas not
done for the private hospital population, as a navigator was not funded.
Information about the family history and recommendations for a genet-
ics referral were incorporated into the mammogram screening report
sent to the ordering physician. High-risk patients fromboth populations
who attended a genetic counseling appointment were offered a
BRCA1/2 test if warranted (based on NCCN guidelines). Genetic testing
was performed by either Myriad Genetic Laboratories or Ambry Genet-
ics. The testing included BRCA1/BRCA2 sequencing and duplication and
deletion analysis. Medical records were retrospectively reviewed to
determine the number of mutation carriers detected and if mutation
carriers followed NCCN management guidelines.
2.3. Expected HBOC Mutation Frequency
To measure the impact of the RST screen for HBOC syndrome, quan-
titation of themutation carrier detection rate compared to the expected
rate is needed, as well as evaluation of prophylactic surgery rates. The
estimated frequency in the general (non-Ashkenazi Jewish) population
of BRCA1 mutations is 0.058% and of BRCA2 mutations, 0.068%
(Antoniou et al., 2002). Based on the US Census data for the Dallas &
Fort Worth area only 1% of our population was of Ashkenazi Jewish an-
cestry. Based on the diversity and size of our mammogram populations,
we predicted there would be 47 and 85mutation carriers in the insured
and underserved populations, respectively.
2.4. Predictive Model of Cancer Reduction in HBOC Patients
Using 186,537 female patients between the ages of 18 and 85 seen at
Parkland and JPS hospitals in 2009 as the simulation population, we de-
veloped models for breast and ovarian cancer that would predict the
cancers in patients with mutations in the BRCA genes based on the ex-
pected age distribution in this population. This simulation population
was used to estimate how many cases of breast and ovarian cancer we
expected to ﬁnd in mutation carriers versus what we actually found
given the age distribution of our patients. Predictions of cancer inci-
dence in patientswhohadnot had preventative surgerieswere calculat-
ed from the cumulative cancer incidence for the BRCA1 and BRCA2
mutation carriers based on reported per year penetrance data (Chen
and Parmigiani, 2007). We deﬁned the “at risk” women as those be-
tween ages 35 and 85who had a BRCAmutation but did not have breast
or ovarian cancer at the start of the followup period (thiswas calculated
by subtracting out the prevalence of breast/ovarian cancers at each age
interval). These at risk women would then be, in simulation, followed
up to age 85. The number of breast/ovarian cancers that would be diag-
nosed each year at each age intervalwas calculated by continually reset-
ting the number “at risk” after each year, and by subtracting out the
number who developed breast/ovarian cancer in the prior year. For
Fig. 1.Mutation detection rates from themammogram screening program.Mammogram patients who completed the RST questionnaire andwere positive for family history suggestive of
HBOCwere then ushered through to genetics for further evaluation. A) Insured population andB)underserved population. This population completed navigation, deﬁned as contacting the
patient at least twice for a genetic referral.
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the breast cancers in the prior year if bilateral prophylactic oophorecto-
my was completed in the patient before age 50 (Rebbeck et al., 2009).
Applying our mutation detection (Fig. 1) and uptake of prophylactic
surgery rates (Fig. 2), we calculated the predicted reduction of breast
and ovarian cancer incidence over 30 years. In our calculations, bilateral
prophylactic mastectomywas assumed to reduce the risk of breast can-
cer by 95% andbilateral oophorectomy (prior to age 50)was assumed to
reduce the risk of breast cancer by 50% and ovarian cancer by 95%
(Rebbeck et al., 2004; Rebbeck et al., 2002; Friebel et al., 2007). A soft-
ware calculator was written using R language speciﬁcally for this use
(see Supplementary data).3. Results
3.1. Mammography Screening for HBOC
Of 96,055 mammogram patients, 34,131 were from the reference
population from the private hospital (Fig. 1A; “insured”) and 61,924
were from the county hospitals (Fig. 1B; “underserved”). The participa-
tion rate in completing the screening tool was 95.9% (92,127 cases
reviewed). Five percent were identiﬁed, based on the RST screen, as
high-risk in each population. Fifty-one percent of high-risk patients in
the underserved population accepted a referral to genetic counseling,
but only half of those kept their appointment (Fig. 1B). Twelve percent
of the insured patients had already been seen by our genetics group,
compared to none in the underserved population. Thirteen percent of
insured patients never seen by genetics were referred to genetic
counseling. Overall, 25% of identiﬁed high-risk insured patients were
seen for genetic testing and85% of those referred kept the scheduled ap-
pointment (Fig. 1A).3.2. Population Diversity
In the underserved population, 58.4% were Caucasian, 37.3% African
American, 3% Asian, and b2% other. Twenty-seven percent of the under-
served reported Hispanic ancestry. In the insured mammogram screen-
ing reference population, 66.5% were Caucasian, 18.5% African
American, 13% other, and 2%Asian and Indian. Hispanic ancestrywas re-
ported in 10.8% of insured patients.
3.3. Genetic Analysis and HBOC Mutation Detection Rate
Seventy-six percent (446/589) of the underserved patients who
were referred due to their family history of cancer underwent BRCA
gene testing. The remaining patients either declined testing or testing
was not indicated after further consultation. Overall, 4.5% of referred pa-
tients (20/446) were found to have a germline mutation.
We identiﬁed only 23.5% (20/85) of predicted BRCA mutation car-
riers in the underserved cohort (Fig. 1B). All of these 20 patients were
newly diagnosedwithHBOC syndrome as a result of themammography
screen and 12 had either a prior (n = 7) or concomitant (n = 5) diag-
nosis of cancer (60% (12/20)). In the insured reference population, we
identiﬁed 36of the 47 (76.6% of expected) predicted BRCAmutation car-
riers (Fig. 1A). Of the 9 newly identiﬁed HBOC syndrome patients, 5 had
either a prior (n= 3) or concomitant (n= 2) diagnosis of breast cancer
(55% (5/9)).
3.4. Surveillance Imaging
We evaluated all female BRCAmutation carriers' compliance to the
2012 NCCN guidelines for surveillance. Clinical data were obtained
from a chart review through June 2015, with a range of follow-up
Fig. 2. Rates of prophylactic surgeries in HBOC patients. Mutation carriers in the insured population (n = 37) and in the underserved population (n = 20) were evaluated for history of
A) prophylacticmastectomy or B) prophylactic oophorectomies. The onemale insured patientwas excluded from the calculations of prophylacticmastectomy rates andNCCN compliance
since guidelines do not exist.
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Fig. 3.Modeling risk reduction for HBOC. Simulation models for cancer prevention in the
different populations. Solid line represents no intervention as a result of genetic testing,
dotted line represents the underserved population and dashed line represents the insured
population. A) HBOC patients were reviewed for whether or not they underwent prophy-
lacticmastectomy and then this frequencywas used tomodel breast cancer risk reduction
over 30 or 40 years. B) HBOC patients were reviewed for whether or not they underwent
prophylactic oophorectomies and then this frequency was used to model ovarian cancer
risk reduction over 30 or 40 years.
1831L.S. Robinson et al. / EBioMedicine 2 (2015) 1827–1833from24 to 44months. Thirty-nine percent of the underservedHBOC pa-
tients met the NCCNmanagement recommendations for surveillance. If
a patient was under active treatment for cancer or if they had stage IV
disease and a mammogram or MRI appointment was missed, we did
not count it as noncompliance with the NCCN guidelines since this
“screening”was not a priority. Twenty-two percent of the underserved
patients were not offered surveillance imaging (MRI/mammography)
because of metastatic cancer. In the patients who did not meet NCCN
guidelines, 32% of patients had no record of an annual mammogram
orMRIand 6% of patients declined all follow-up. In the insured reference
population with HBOC syndrome that were followed at our institution,
the patient compliance to the NCCN management guidelines was 72%.
3.5. Cancer Stage of Mutation Carriers
Of the 12 underserved patients with HBOC syndrome with cancer,
the average age was 52 and 83% were minorities. Of the four patients
with ovarian cancer, all had a stage III disease. Of the 8 breast cancer pa-
tients, one was at stage I, one was at stage II, four were at stage III, one
was stage IV and one patient's cancer stage was unknown. Overall,
82% of uninsured patients with known staging had an advanced cancer
(stage III or IV).
Thirteen of the insured patients with HBOC syndrome had cancer,
two with ovarian and eleven with breast cancer, prior to or at mammo-
gram screening. The average age was 51.9 and 23% were minorities. Of
the two cases of ovarian cancer, bothwere stage III. Of the insured breast
cancer patients, threewere stage 0, four were stage I, threewere stage II
and in one case, stage was not available. There were no insured breast
cancer patients with advanced stage cancer (stage III or IV). Twenty-
two percent of insured patients with known staging had an advanced
cancer.
3.6. Prophylactic Surgery
We next assessed whether patients had prophylactic mastectomies
or oophorectomies (Fig. 2). Of the insured reference patients in whom
a genetic mutation was detected prior to the mammogram screening
program, 30% elected to have prophylactic mastectomies. Seventy-
eight percent of themutation carriers identiﬁed as a result of themam-
mogram screening program elected prophylactic mastectomy, with the
overall rate in the insured population of 40.5%.Within the public hospi-
tal setting, 37.5% of the cancer patients elected prophylactic contralater-
almastectomy and 12.5% of the unaffected patients elected prophylactic
bilateral mastectomies (25% overall) (Fig. 2A). In regard to prophylactic
oophorectomy, 71% of the insured eligible (i.e. those patients over the
age of 35with at least one intact ovary) mutation carriers newly identi-
ﬁed by the RST screen (N= 5/7) elected to have surgery and 71% of the
previously identiﬁed mutation carriers elected the same (N = 10/14).
For the uninsured population, 40% of the identiﬁed eligible HBOC pa-
tients (N = 2/5) elected to have prophylactic oophorectomies (Fig.
2B). All patients with a prior history of oophorectomy for unrelated
medical reasons were excluded from this analysis.
Based on the uptake of prophylactic surgeries in BRCAmutation car-
riers, we predicted an insigniﬁcant 8.8% reduction in breast and ovarian
cancer in the underserved population. In contrast, in the insured refer-
ence population of identiﬁed BRCAmutation carriers, cancer risk reduc-
tion was signiﬁcantly greater at 56.6% for breast cancer (Fig. 3A; p b
0.0075, chi-square, 30 year follow up) and 51.3% for ovarian cancer
(Fig. 3B; p b 0.0117, chi-square, 30 year follow up) if the proposed mu-
tation detection rate, with all of the caveats associatedwith this calcula-
tion, was truly 76.6%.
4. Discussion
The aim of our study was to determine if screening for a family his-
tory of cancer in underserved mammography populations wouldidentify patients at high risk for HBOC syndrome that would then lead
to genetic testing and increased cancer prevention.We found low levels
of genetic screening and adherence to management guidelines in the
underserved HBOC syndrome patients. The number of unaffected pa-
tients in the underserved population identiﬁed as BRCA1/2 mutation
carriers was lower than our reference insured population and those
who were identiﬁed had fewer preventative surgeries. The data were
used to model cancer prevention frequency and a signiﬁcant decrease
in cancer incidence was only found in the insured reference population.
Our model calculates the reduction of cancer incidence in HBOC pa-
tients by taking the population's age distribution, mutation detection
rate and frequency of prophylactic surgery into account. From these
data, our model predicted only an 8.8% reduction in the both the breast
and ovarian cancer rate over 30 years in the underserved. Although we
did not have a true control population of insured patientsmanaged by a
single institution, themutation detection rate and the rate of prophylac-
tic surgeries were higher in this population. Using the data from this
“reference” population we illustrate how themodel can predict that in-
creasing mutation detection frequency and prophylactic surgery rates
can be used as benchmarks for increasing cancer prevention in patients
with HBOC syndrome.
Although this model only addresses the reduction in cancer incidence
over time based on the prophylactic surgery and mutation detection
rates, patient compliance to other NCCNmanagement recommendations
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breast cancers in patients with HBOC syndrome. The compliance with
NCCN HBOC syndrome management guidelines in the underserved pop-
ulation studied here was only 39%. Improved genetic navigation and fur-
ther research to understand and quantify patient barriers to care may
increase the NCCN compliance rates in these patients. General barriers
for health care in the underserved such as ﬁnancial constraints, transpor-
tation challenges, limited education and inability to take time offwork are
obvious candidates. The reduced compliance of the underserved popula-
tionwith NCCN surveillance guidelinesmirrors the reduced uptake of ge-
netic referrals and low completion rates of prophylactic surgeries.
For the underserved mammography patients, but not the insured
patients, genetic navigators were available to contact and track patients
identiﬁed as high-risk. The underserved patients are likely to beneﬁt
more from services of a genetic navigator because they are often more
difﬁcult to reach and less informed than the insured population. On a
more practical note, funds for genetic navigators in this study were
not available for the insured reference population. The lack of naviga-
tion for the insured may be a contributing factor to the surprisingly
low frequency of referred insured patients (Fig. 1A). Further, although
chart documentation of genetic counseling was absent in 70% of the
high-risk insured patients recommended for genetic counseling, this
does not mean they did not have genetic analysis at an outside site. In
fact, at least 20% of insured mammogram patients are referred to UT
Southwestern from outside providers, making it unknown whether
the family history of cancer led them to receive genetic analysis at dif-
ferent institutions. However, if these analyseswere done on the outside,
the mutation rate in the insured population would only increase and
make the differences between the insured and the underserved cohorts
greater.
Without knowing the outcomes of the non-referred patients, we
limited comparisons of the insured and underserved patients to those
who had documented genetic analyses at our institution. Although
this is a study limitation, we were comfortable in our use of these data
in our model because when compared to other reports of rates of pre-
ventative measures taken, they are similar to our reference population
(Skytte et al., 2010; Singh et al., 2013; Schwartz et al., 2012). The pub-
lished rates from smaller populations are also higher than the rates
we observed in our underserved population emphasizing the greater
need for improvement in the underserved.
There was one area of cancer prevention where the underserved
fared better than the insured reference population and that was the
rate of documented referral of patients for genetic evaluation. This
may have been because the patient navigator was available for the
underserved patients but not for the insured patients. Certainly, if a nav-
igator had not been used for the underserved, wewould have identiﬁed
even fewer BRCAmutation carriers.
We were surprised by the large fraction of insured patients who did
not have documented genetic analysis despite their positive family his-
tory of cancer. Possible explanations for this low frequency include:
1) these patients were counseled and tested at another hospital;
2) the primary doctor and patient revised the original family history
so that genetics referral was no longer warranted; or 3) the patients
should have been referred and were not. For the underserved popula-
tions, patients were easier to follow as our safety net hospitals systems
(Parkland Memorial, and JPS) are the only places these patients receive
affordable health care. Genetic testing for cancer predisposition is not a
simple decision and as shown here, efforts to navigate all of our patients
(not just the underserved) and educate both patients and their physi-
cians, to improve cancer prevention, is needed.
Another potential limitation of our computer model is that we in-
cluded prophylactic oophorectomy as a factor that predicts breast can-
cer reduction by 50% in BRCA1/2 mutation carriers (Rebbeck et al.,
2009). A recent report cited potential bias in many of the past studies
that predicted oophorectomy reduced breast cancer risk (Heemskerk-
Gerritsen et al., 2015). At this time, more long term data are needed tounderstand the impact of oophorectomy on breast cancer incidence in
BRCA1/2mutation carriers.
Although screening for a high genetic risk for cancer saves not only
the patient's life but also their family members' lives, it is likely many
unaffected individuals and their physicians are unaware of the beneﬁts
of knowing their genetic risks. For example, we were surprised at the
number of newly identiﬁed HBOC patients who had a prior history of
breast or ovarian cancer but had not had a genetic analysis (35% (7/
20) of underserved and 33% (3/9) of insured patients). Screening of
primary care and mammography populations will continue to identify
affected patients who had not previously been offered genetic screen-
ing; this emphasizes that screening for BRCA1/2 mutation carriers
must be multifaceted and not just occur in the oncology clinic.
Decreasing the cancer incidence in HBOC patients or other heredi-
tary cancer syndromes can only be achieved by evaluation of the entire
screening progress. Offeringwomen BRCA1/2 gene testing is not enough
to decrease cancer risk on a population basis. There are two main areas
that contribute to the decreased cancer prevention in the underserved
HBOC patients. First, we found that only a quarter of the underserved
patients came in for genetic analysis. Further research is needed to de-
termine reasons patients decline genetic analysis and potential testing.
Second, if they do come in, a need for an increased acceptance of pro-
phylactic oophorectomies and mastectomies will increase the preven-
tion of ovarian and breast cancer incidence.
In sum, even though genetic testing to identify BRCA1/2 mutation
carriers has been integral to oncology practices for almost 20 years, little
data have been reported on the outcomes of these genetic screening
programs in large diverse primarily unaffected populations. Although
we identiﬁed only twenty underserved patients with HBOC syndrome
through mammography screening of 61,924 patients, this is the largest
underserved population at risk that has been identiﬁed atmammography
and followed for the preventative measures taken. By isolating and
quantifying key steps to cancer risk reduction, we have established a pre-
liminary baseline quality measure to calculate where we stand and to ef-
fectively guide us as wemove to 100% compliance with evidenced-based
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